William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom.
Biochem Pharmacol. 2011 Dec 15;82(12):1919-29. doi: 10.1016/j.bcp.2011.09.009. Epub 2011 Sep 16.
Osteoarthritis is a highly prevalent and disabling disease for which we do not have a cure. The identification of suitable molecular targets is hindered by the lack of standardized, reproducible and convenient screening assays. Following extensive comparisons of a number of chondrocytic cell lines, culture conditions, and readouts, we have optimized an assay utilizing C-28/I2, a chondrocytic cell line cultured in high-density micromasses. Utilizing molecules with known effects on cartilage (e.g. IL-1β, TGFβ1, BMP-2), we have exploited this improved protocol to (i) evoke responses characteristic of primary chondrocytes; (ii) assess the pharmacodynamics of gene over-expression using non-viral expression vectors; (iii) establish the response profiles of known pharmacological treatments; and (iv) investigate their mechanisms of action. These data indicate that we have established a medium-throughput methodology for studying chondrocyte-specific cellular and molecular responses (from gene expression to rapid quantitative measurement of sulfated glycosaminoglycans by Alcian blue staining) that may enable the discovery of novel therapeutics for pharmacological modulation of chondrocyte activation in osteoarthritis.
骨关节炎是一种高发且致残性疾病,目前尚无治愈方法。由于缺乏标准化、可重现和方便的筛选检测方法,合适的分子靶标难以确定。在对许多软骨细胞系、培养条件和检测方法进行广泛比较后,我们优化了利用 C-28/I2 (一种在高密度微团中培养的软骨细胞系)的检测方法。利用已知对软骨有作用的分子(例如 IL-1β、TGFβ1、BMP-2),我们利用该改进方案:(i)引发与原代软骨细胞相似的反应;(ii)评估非病毒表达载体基因过表达的药效动力学;(iii)确定已知药物治疗的反应谱;(iv)研究其作用机制。这些数据表明,我们已经建立了一种用于研究软骨细胞特异性细胞和分子反应的高通量方法(从基因表达到通过阿利新蓝染色快速定量测量硫酸化糖胺聚糖),这可能有助于发现用于骨关节炎中软骨细胞激活的药理学调节的新型治疗药物。